NCT01165346 (CKNO-HEP) is a Phase 2 clinical trial of Fiducials in Hepatocellular Carcinoma, sponsored by Centre Oscar Lambret.

Who is sponsoring NCT01165346?

NCT01165346 is sponsored by Centre Oscar Lambret.

What drugs are being tested in NCT01165346?

Interventions in NCT01165346: Fiducials, CyberKnife.

What condition does NCT01165346 study?

NCT01165346 studies Hepatocellular Carcinoma.

Is NCT01165346 still recruiting?

NCT01165346 is currently completed. Last updated 13 March 2026.

Last reviewed 2026-03-13 · How we verify

NCT01165346: CKNO-HEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stereotaxic Irradiation of Hepatocellular Carcinoma

Completed Phase 2 Last updated 13 March 2026

What this trial tests

Phase 2 trial testing Fiducials in Hepatocellular Carcinoma in 44 participants. Completed in 19 April 2018.

Timeline

31 August 2009

Primary endpoint
31 March 2016

19 April 2018

Quick facts

Lead sponsor	Centre Oscar Lambret
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	44
Start date	31 August 2009
Primary completion	31 March 2016
Estimated completion	19 April 2018
Sites	4 locations across France

Drugs / interventions tested

Fiducials
CyberKnife — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Centre Oscar Lambret — full company profile →

Who can join

18 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days for a total of 45 Gy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma.
Oldrini G, Huertas A, Renard-Oldrini S, Taste-George H, et al · · 2017 · cited 23× · PMID 28441447 · DOI 10.1371/journal.pone.0176118

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Centre Oscar Lambret trials

Trials by the same sponsor.

NCT07507773 — Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the · Phase 2 · not yet recruiting
NCT06807164 — Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome · Phase 2 · recruiting
NCT06969833 — Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma · NA · recruiting
NCT06181201 — Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer · terminated
NCT05286684 — Feasibility of Exosome Analysis in Cerebrospinal Fluid During the Diagnostic Workup of Metastatic Meningitis · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01165346 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Oscar Lambret
Last refreshed: 13 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01165346.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing